CSOP Hang Seng Biotech ETF (03174.HK) Rises 2.54% in Early Trading, NAV Per Unit at HK$3.304
NewTimeSpace News: As at 09:42 on August 4, 2026, CSOP Hang Seng Biotech ETF (03174.HK) rose 2.54% to HK$3.394. The ETF traded 407,800 shares with a turnover value of HK$1.3883 million, an average price of HK$3.404, volume ratio of 7.44, turnover rate of 0.16% and amplitude of 1.09%. Its current net asset value per unit stands at HK$3.304, assets under management of HK$839 million, with each board lot consisting of 100 shares.
CSOP Hang Seng Biotech ETF (03174.HK) tracks the Hang Seng Biotech Index. The index focuses on leading biotech companies listed in Hong Kong, covering sectors including innovative drugs, CXO, vaccines and gene therapy.
NewTimeSpace Disclaimer: All content herein is the original work of NewTimeSpace. Any reproduction, reprinting, or use of this content in any other manner must clearly indicate the source as "NewTimeSpace". NewTimeSpace and its authorized third-party information providers strive to ensure the accuracy and reliability of the data, but do not guarantee the absolute correctness thereof. This content is for reference only and does not constitute any investment advice. All transaction risks shall be borne by the user.
- CSOP Hang Seng Biotech ETF (03174.HK) Up 4.32% as FDA Grants Priority Review to BeiGene Combo
- CSOP HS Biotech(03174.HK) +2.81%, Hengrui 9M net profit up 20.38%
- Chinese Innovative Drugs Set Record Share of ESMO Late-Breaking Abstracts; CSOP Hang Seng Biotech ETF (03174.HK) Rises 0.81% Intraday
- CSOP Hang Seng Biotech ETF (03174.HK) Rises 0.55% Intraday as Record 29 Chinese Studies Make ESMO Late-Breaker List
- HANSOH's ADC Licensing Deal with Roche Worth up to USD 15 Billion and a Record Share of Chinese Studies at ESMO LBA; CSOP Hang Seng Biotech ETF (03174.HK) Rises 2.09% Against the Trend on 20 October